Q-omics provides the consensus-scored OR52D1 profile across patient tissues and cancer cell-line models. OR52D1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OR52D1 is differentially expressed in 2, with the highest sampling consensus in BLCA. Additionally, OR52D1 RNA expression shows 8,892 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, BLCA, and TGCT as cancer lineages where OR52D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR52D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR52D1 survival associations across molecular data types. OR52D1 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR52D1 RNA expression–survival associations across cancer types. High OR52D1 expression shows unfavorable associations in KIRC, KICH, TGCT, BLCA and DLBC, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for OR52D1 RNA expression.
This table summarizes OR52D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR52D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR52D1 shows lower tumor expression in LUAD and higher tumor expression in BLCA. The BLCA box plot shows higher OR52D1 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p = .025).
This table shows molecular features associated with OR52D1 in patient tissues and cancer cell lines. In patient samples, OR52D1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OR52D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
